Table 1 Effects of myosin Va manipulation on the exocytosis of DCVs in different cell types
Cell typeExperimental manipulationObservationsReference
Chromaffin cellsAnti-myosin Va head antibodyReduced noradrenaline secretion[28]
Anti-myosin Va neck antibodyFewer exocytotic events[29]
PC12 cellsMyoVa-tailReduced mobility in the F-actin cortex; fewer exocytotic events[4]; T. Kögel, R. Rudolf and H.-H. Gerdes, unpublished work
siRNA against myosin VaMore exocytotic eventsT. Kögel, R. Rudolf and H.-H. Gerdes, unpublished work
Pancreatic β-cells (MIN6)siRNA against myosin VaReduced insulin secretion[8]
MyoVa-tailFewer docked DCVs; fewer exocytotic events[8]
Pancreatic β-cells (INS-1E)siRNA against myosin VaReduced growth hormone secretion[32]
siRNA against myosin Va or Slac-2c-/MyRIPSmaller capacitance increase (=fewer membrane fusion events)[32]
anti-MyoVa-tail antibodySmaller capacitance increase (=fewer membrane fusion events)[32]
BON cellsMyoVa-tail or siRNA against myosin VaHigher mobility in actin cortex; fewer docked vesicles; fewer long-term docking events; fewer exocytotic events[7]
Hippocampal neuronsMyoVa-tailMore exocytotic events[41]